nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-977Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЭволюция и болезнь (Лекция)Evolution and disease LectureБагровЯ. Ю.BagrovY. Y.noemail@neicon.ruМанусоваН. Б.ManusovaN. B.nmanus@rambler.ruУчреждение Российской академии наук «Институт эволюционной физиологии и биохимии им. И.М. Сеченова», г. Санкт-ПетербургRussian Federation20101706202512147Copyright © Багров Я.Ю., Манусова Н.Б., 20252025Багров Я.Ю., Манусова Н.Б.Bagrov Y.Y., Manusova N.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/977

В статье на основании данных литературы и собственных клинических и лабораторных исследований излагается концепция роли эволюции в патологии человека. Согласно нашей точке зрения кажущаяся неадекватность многих хронических патологических реакций обусловлена тем, что подобные реакции возникли и закрепились в эволюции как способы компенсации острых патологических состояний. В условиях борьбы за существование хронические заболевания не могли быть фактором эволюции. Невозможность исправить хронические патологические состояния мерами, выработанными в процессе эволюции, может быть ликвидирована лишь с помощью достижений технического прогресса.

A concept concerning the role of evolution in human disease is presented on the basis of literature data and own clinical and experimental observations. According to our understanding, a seeming inadequacy of many chronic pathologic processes is based on the fact that such processes have emerged and became reinforced in the course of evolution primarily as the compensatory tools aimed to override the acute, but not chronic, pathological processes. Since in the course of natural selection, chronic diseases were not a factor of evolution, we believe that the inability to fix chronic disease by means of natural evolution could be fixed only by the technological evolution.

почкаэволюциянатрийурезотекиkidneyevolutionnatriuresisoedemaReferencesБагров Я.Ю., Васильева В.Ф., Воробьева К.П. и др. Функция почек и активность Na+-К+-АТФазы и сукцинатдегидрогеназы в клетках почечных канальцев крыс с сужением грудного отдела нижней полой вены // Кардиология. 1979. № 2. С. 80–84.Багров Я.Ю., Васильева В.Ф., Воробьева К.П. и др. Функция почек и активность Na+-К+-АТФазы и сукцинатдегидрогеназы в клетках почечных канальцев крыс с сужением грудного отдела нижней полой вены // Кардиология. 1979. № 2. С. 80–84.Гинецинский А.Г. Об эволюции функций и функциональной эволюции. М.–Л. 1961.Гинецинский А.Г. Об эволюции функций и функциональной эволюции. М.–Л. 1961.Орбели Л.А. О взаимоотношениях эволюционной физиологии и медицины. Ленинград. 1958.Орбели Л.А. О взаимоотношениях эволюционной физиологии и медицины. Ленинград. 1958.Bell T.D., Welch W.J. Regulation of renal arteriolar tone by adenosine: novel role for type 2 receptors // Kidney Int. 2009. Vol. 75 (8). P. 793–799.Bell T.D., Welch W.J. Regulation of renal arteriolar tone by adenosine: novel role for type 2 receptors // Kidney Int. 2009. Vol. 75 (8). P. 793–799.Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin // Am J Cardiol. 2005. Vol. 2 (95;9A). P. 8–13.Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin // Am J Cardiol. 2005. Vol. 2 (95;9A). P. 8–13.DiBona G.F. Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function // Hypertension. 2000. Vol. 36 (6). P. 1083–1088.DiBona G.F. Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function // Hypertension. 2000. Vol. 36 (6). P. 1083–1088.Di Sole F. Adenosine and renal tubular function // Curr. Opin Nephrol. Hypertens. 2008. Vol. 17 (4). P. 399–407.Di Sole F. Adenosine and renal tubular function // Curr. Opin Nephrol. Hypertens. 2008. Vol. 17 (4). P. 399–407.Dohadwala M.M., Givertz M.M. Role of adenosine antagonism in the cardiorenal syndrome // Cardiovasc. Ther. 2008. Vol. 26 (4). P. 276–286.Dohadwala M.M., Givertz M.M. Role of adenosine antagonism in the cardiorenal syndrome // Cardiovasc. Ther. 2008. Vol. 26 (4). P. 276–286.Feng M.G., Navar L.G. Adenosine A2 receptor activation attenuates afferent arteriolar autoregulation during adenosine receptor saturation in rats // Hypertension. 2007. Vol. 50 (4). P. 744–749.Feng M.G., Navar L.G. Adenosine A2 receptor activation attenuates afferent arteriolar autoregulation during adenosine receptor saturation in rats // Hypertension. 2007. Vol. 50 (4). P. 744–749.Franco M., Pérez-Mendéz O., Martínez F. Interaction of intrarenal adenosine and angiotensin II in kidney vascular resistance // Curr. Opin Nephrol Hypertens. 2009. Vol. 18 (1). P. 63–67.Franco M., Pérez-Mendéz O., Martínez F. Interaction of intrarenal adenosine and angiotensin II in kidney vascular resistance // Curr. Opin Nephrol Hypertens. 2009. Vol. 18 (1). P. 63–67.Garovic V, Textor SC. Renovascular hypertension: current concepts // Semin Nephrol. 2005. Vol. 25 (4). P. 261–271.Garovic V, Textor SC. Renovascular hypertension: current concepts // Semin Nephrol. 2005. Vol. 25 (4). P. 261–271.Gildea J.J. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance // Curr. Opin. Nephrol. Hypertens. 2009. Vol. 18 (1). P. 28–32.Gildea J.J. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance // Curr. Opin. Nephrol. Hypertens. 2009. Vol. 18 (1). P. 28–32.Kaname S., Fujita T. Angiotensin II and the kidney // Nippon Rinsho. 1999. Vol. 57 (5). P. 1103–1109.Kaname S., Fujita T. Angiotensin II and the kidney // Nippon Rinsho. 1999. Vol. 57 (5). P. 1103–1109.Mirzoyev Z., Anavekar N.S., Chen H.H. Renal and humoral pathophysiological actions of angiotensin II in congestive heart failure // Drugs Today (Barc). 2005. Vol. 41 (2). P. 129–39.Mirzoyev Z., Anavekar N.S., Chen H.H. Renal and humoral pathophysiological actions of angiotensin II in congestive heart failure // Drugs Today (Barc). 2005. Vol. 41 (2). P. 129–39.Nishiyama A., Inscho E.W., Navar L.G. Interactions of adenosine A1 and A2a receptors on renal microvascular reactivity // Am. J. Physiol. Renal Physiol. 2001. Vol. 280 (3). P. 406–414.Nishiyama A., Inscho E.W., Navar L.G. Interactions of adenosine A1 and A2a receptors on renal microvascular reactivity // Am. J. Physiol. Renal Physiol. 2001. Vol. 280 (3). P. 406–414.Shah R.H., Frishman W.H. Adenosine1 receptor antagonism: a new therapeutic approach for the treatment of decompensated heart failure // Cardiol. Rev. 2009. Vol. 17 (3). P. 125–131.Shah R.H., Frishman W.H. Adenosine1 receptor antagonism: a new therapeutic approach for the treatment of decompensated heart failure // Cardiol. Rev. 2009. Vol. 17 (3). P. 125–131.Silverberg D.S., Wexler D., Iaina A. et al. Anemia, chronic renal disease and congestive heart failure – the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists // Int. Urol. Nephrol. 2006. Vol. 38 (2). P. 295–310.Silverberg D.S., Wexler D., Iaina A. et al. Anemia, chronic renal disease and congestive heart failure – the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists // Int. Urol. Nephrol. 2006. Vol. 38 (2). P. 295–310.Silverberg D.S., Wexler D., Iaina A. et al. The interaction between heart failure and other heart diseases, renal failure, and anemia // Semin. Nephrol. 2006. Vol. 26 (4). P. 296–306.Silverberg D.S., Wexler D., Iaina A. et al. The interaction between heart failure and other heart diseases, renal failure, and anemia // Semin. Nephrol. 2006. Vol. 26 (4). P. 296–306.Sladek C.D., Song Z. Regulation of vasopressin release by co-released neurotransmitters: mechanisms of purinergic and adrenergic synergism // Prog. Brain. Res. 2008. Vol. 170. P. 93–107.Sladek C.D., Song Z. Regulation of vasopressin release by co-released neurotransmitters: mechanisms of purinergic and adrenergic synergism // Prog. Brain. Res. 2008. Vol. 170. P. 93–107.Smilde T.D., Damman K., Van der Harst P. et al. Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure // Clin Res Cardiol. 2009. Vol. 98 (2). P. 121–129.Smilde T.D., Damman K., Van der Harst P. et al. Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure // Clin Res Cardiol. 2009. Vol. 98 (2). P. 121–129.Valles P., Wysocki J., Batlle D. Angiotensin II and renal tubular ion transport // Scientific World Journal. 2005. Vol. 29 (5). P. 680–690.Valles P., Wysocki J., Batlle D. Angiotensin II and renal tubular ion transport // Scientific World Journal. 2005. Vol. 29 (5). P. 680–690.Vallon V., Osswald H. Adenosine receptors and the kidney // Handb. Exp. Pharmacol. 2009. Vol. 193. P. 443–470.Vallon V., Osswald H. Adenosine receptors and the kidney // Handb. Exp. Pharmacol. 2009. Vol. 193. P. 443–470.

The authors declare that there are no conflicts of interest present.